CL2008002860A1 - Polipeptido; polinucleotido que lo codifica; vector y fago aislado que comprenda este polinucleotido; anticuerpo que se une a este polipeptido; molecula de fusion que comprende este polipeptido; celula huesped metanogena que comprende el vector; composicion farmaceutica que comprende el polinucleotido. - Google Patents
Polipeptido; polinucleotido que lo codifica; vector y fago aislado que comprenda este polinucleotido; anticuerpo que se une a este polipeptido; molecula de fusion que comprende este polipeptido; celula huesped metanogena que comprende el vector; composicion farmaceutica que comprende el polinucleotido.Info
- Publication number
- CL2008002860A1 CL2008002860A1 CL2008002860A CL2008002860A CL2008002860A1 CL 2008002860 A1 CL2008002860 A1 CL 2008002860A1 CL 2008002860 A CL2008002860 A CL 2008002860A CL 2008002860 A CL2008002860 A CL 2008002860A CL 2008002860 A1 CL2008002860 A1 CL 2008002860A1
- Authority
- CL
- Chile
- Prior art keywords
- polypeptide
- polynucleotide
- cells
- vector
- fagtium
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 11
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 11
- 102000040430 polynucleotide Human genes 0.000 title abstract 4
- 108091033319 polynucleotide Proteins 0.000 title abstract 4
- 239000002157 polynucleotide Substances 0.000 title abstract 4
- 230000004927 fusion Effects 0.000 title 1
- 230000000696 methanogenic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000006698 induction Effects 0.000 abstract 3
- 230000000813 microbial effect Effects 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/641—Cysteine endopeptidases (3.4.22)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/20—Reduction of greenhouse gas [GHG] emissions in agriculture, e.g. CO2
- Y02P60/22—Methane [CH4], e.g. from rice paddies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97510407P | 2007-09-25 | 2007-09-25 | |
| US98984007P | 2007-11-22 | 2007-11-22 | |
| US98984107P | 2007-11-22 | 2007-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008002860A1 true CL2008002860A1 (es) | 2009-06-05 |
Family
ID=40511642
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008002859A CL2008002859A1 (es) | 2007-09-25 | 2008-09-25 | Péptido señal con actividad de permeabilización de células microbianas; vector; célula huésped; molécula conjugada que lo comprende; y método para permeabilizar una célula microbiana. |
| CL2008002861A CL2008002861A1 (es) | 2007-09-25 | 2008-09-25 | Polipeptido aislado de m. ruminantium; vector, molecula conjugada y celula huesped que comprenden dicho polipeptido; anticuerpo o fragmento que se une al polipeptido; composicion farmaceutica que comprende la molecula conjugada; metodo para dirigir una celula metanogena para identificacion, aislamiento o inhibicion. |
| CL2008002860A CL2008002860A1 (es) | 2007-09-25 | 2008-09-25 | Polipeptido; polinucleotido que lo codifica; vector y fago aislado que comprenda este polinucleotido; anticuerpo que se une a este polipeptido; molecula de fusion que comprende este polipeptido; celula huesped metanogena que comprende el vector; composicion farmaceutica que comprende el polinucleotido. |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008002859A CL2008002859A1 (es) | 2007-09-25 | 2008-09-25 | Péptido señal con actividad de permeabilización de células microbianas; vector; célula huésped; molécula conjugada que lo comprende; y método para permeabilizar una célula microbiana. |
| CL2008002861A CL2008002861A1 (es) | 2007-09-25 | 2008-09-25 | Polipeptido aislado de m. ruminantium; vector, molecula conjugada y celula huesped que comprenden dicho polipeptido; anticuerpo o fragmento que se une al polipeptido; composicion farmaceutica que comprende la molecula conjugada; metodo para dirigir una celula metanogena para identificacion, aislamiento o inhibicion. |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US8592556B2 (enExample) |
| EP (5) | EP3327030B1 (enExample) |
| JP (5) | JP5558356B2 (enExample) |
| CN (4) | CN102015755A (enExample) |
| AR (3) | AR068553A1 (enExample) |
| AU (4) | AU2008304018A1 (enExample) |
| BR (5) | BRPI0817299A8 (enExample) |
| CA (3) | CA2700129C (enExample) |
| CL (3) | CL2008002859A1 (enExample) |
| DK (3) | DK2203466T3 (enExample) |
| ES (3) | ES2587595T3 (enExample) |
| MX (3) | MX2010003328A (enExample) |
| NZ (1) | NZ745324A (enExample) |
| RU (1) | RU2528854C2 (enExample) |
| UY (3) | UY31361A1 (enExample) |
| WO (3) | WO2009041830A2 (enExample) |
| ZA (1) | ZA201001933B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0817299A8 (pt) * | 2007-09-25 | 2019-01-29 | Pastoral Greenhouse Gas Res Limited | vacinas e componentes de vacina para inibição de células microbianas |
| GB0815484D0 (en) | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
| KR101701890B1 (ko) * | 2009-06-26 | 2017-02-02 | 뤼산도 아게 | 항균제 |
| EP3058950B1 (en) * | 2009-06-26 | 2020-03-04 | Lysando AG | Antimicrobial agents |
| AR077992A1 (es) | 2009-08-27 | 2011-10-05 | Pastoral Greenhouse Gas Res Ltd | Secuencia del genoma completo del metanogeno methanobrevibacter ruminantium |
| SG184836A1 (en) * | 2010-04-27 | 2012-11-29 | Lysando Ag | Method of reducing biofilms |
| EP2899200B1 (en) * | 2012-09-19 | 2020-05-06 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| CN105658796B (zh) * | 2012-12-12 | 2021-10-26 | 布罗德研究所有限公司 | 用于序列操纵的crispr-cas组分系统、方法以及组合物 |
| US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
| US9885033B2 (en) | 2013-03-15 | 2018-02-06 | The General Hospital Corporation | Increasing specificity for RNA-guided genome editing |
| US10011850B2 (en) | 2013-06-21 | 2018-07-03 | The General Hospital Corporation | Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing |
| CA2930015A1 (en) | 2013-11-07 | 2015-05-14 | Editas Medicine, Inc. | Crispr-related methods and compositions with governing grnas |
| WO2016073433A1 (en) * | 2014-11-06 | 2016-05-12 | E. I. Du Pont De Nemours And Company | Peptide-mediated delivery of rna-guided endonuclease into cells |
| CN104789675A (zh) * | 2015-04-15 | 2015-07-22 | 江苏师范大学 | 一种检测荷斯坦奶牛瘤胃微生物的方法 |
| WO2016178207A1 (en) * | 2015-05-04 | 2016-11-10 | Ramot At Tel-Aviv University Ltd. | Methods and kits for fragmenting dna |
| US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| US9926546B2 (en) | 2015-08-28 | 2018-03-27 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| DK3484996T3 (da) * | 2016-07-14 | 2020-12-07 | Basf Se | Fermenteringsmedium, der omfatter et chelateringsmiddel |
| KR102747205B1 (ko) * | 2016-12-29 | 2024-12-31 | 일루미나, 인코포레이티드 | 세포 구획 내의 생체분자에 대한 직교 접근 및 그의 태그부착을 위한 분석 시스템 |
| WO2018126499A1 (zh) | 2017-01-05 | 2018-07-12 | 深圳迈瑞生物医疗电子股份有限公司 | 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物 |
| US10745439B2 (en) * | 2017-03-20 | 2020-08-18 | Regents Of The University Of Minnesota | Kinase substrates and methods of use thereof |
| WO2019147743A1 (en) | 2018-01-26 | 2019-08-01 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| CN116349651A (zh) * | 2018-03-19 | 2023-06-30 | 瑞泽恩制药公司 | 使用crispr/cas系统对动物进行转录调制 |
| CN113646330A (zh) | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
| JP7619941B2 (ja) | 2018-11-14 | 2025-01-22 | アイバイオ, インク. | Cd25抗体 |
| CN109627301B (zh) * | 2019-02-18 | 2022-08-05 | 浙江新银象生物工程有限公司 | Nisin固体稳定剂开发及应用 |
| WO2021185948A1 (en) * | 2020-03-19 | 2021-09-23 | Micreos Human Health B.V. | A stabilized protein of interest |
| US20230072496A1 (en) * | 2020-04-10 | 2023-03-09 | Liberty Biosecurity, Llc | Polypeptide compositions and uses thereof |
| CN112143747B (zh) * | 2020-09-09 | 2022-09-13 | 昆明理工大学 | 一种噬菌体裂解酶及其基因、基因重组表达载体与应用 |
| PT4037666T (pt) | 2020-12-08 | 2024-06-25 | Ruminant Biotech Corp Ltd | Aperfeiçoamentos de dispositivos e métodos para administração de substâncias a animais |
| CN112961217B (zh) * | 2021-03-19 | 2022-11-08 | 江苏元本生物科技有限公司 | 一种靶向Siglec-15的噬菌体多肽 |
| CN113121705B (zh) * | 2021-04-19 | 2023-03-24 | 成都英普博集生物科技有限公司 | 用于制备短肽混合物的融合蛋白、目的多肽、短肽混合物的制备方法及应用 |
| EP4554616A1 (en) * | 2022-07-11 | 2025-05-21 | Arkea Bio Corp. | Compositions and methods for reducing methane emissions in ruminant populations |
| CN115417927A (zh) * | 2022-09-08 | 2022-12-02 | 南京松天盛科生物科技有限公司 | 小鼠腹水致敏物及其应用 |
| AR130970A1 (es) * | 2022-11-03 | 2025-02-05 | Helix Nanotechnologies Inc | Vacunas ruminales y metanógenas y usos de estas |
| CN115938486B (zh) * | 2022-12-06 | 2023-11-10 | 内蒙古农业大学 | 基于图神经网络的抗菌性乳酸菌株筛选方法 |
| WO2025219570A1 (en) | 2024-04-17 | 2025-10-23 | Johannes Kepler Universität Linz | Composition for inhibiting protein translocation and methods using the same |
| WO2025233675A1 (en) * | 2024-05-10 | 2025-11-13 | Institut Pasteur | Use of talosaminidase to regulate populations of archaeal methanogens in industrial, agricultural and medical settings |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US159861A (en) * | 1875-02-16 | Improvement in brooms | ||
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| JPH01500746A (ja) * | 1983-05-03 | 1989-03-16 | エス.エス.エム.インターナショナル ケミカル カンパニー リミテッド | 改善された医薬活性を有する組成物および獣医用の目的にそれを使用すること |
| GB8815968D0 (en) * | 1988-07-05 | 1988-08-10 | Pfizer Ltd | Veterinary devices |
| JPH05219927A (ja) * | 1992-02-14 | 1993-08-31 | Gumma Pref Gov | 飼料の混合装置及び混合飼料の製造方法 |
| JP3651915B2 (ja) * | 1993-06-30 | 2005-05-25 | 財団法人神奈川科学技術アカデミー | シグナル配列ペプチドをコードするdna断片の探索法及びそのためのベクター |
| DK0724454T3 (da) * | 1993-10-19 | 2004-07-12 | Commw Scient Ind Res Org | Fremgangsmåde til forbedring af drövtyggerdyrs eller drövtyggerlignende dyrs udnyttelse af næringsstoffer |
| JPH09507121A (ja) | 1993-10-26 | 1997-07-22 | アフィマックス テクノロジーズ ナームロゼ ベノートスハップ | 生物学的チップ上の核酸プローブアレー |
| NZ278977A (en) | 1994-01-20 | 1997-03-24 | Pastoral Agric Res Inst Nz Ltd | Sustained release bolus for ruminants |
| ES2207644T3 (es) | 1994-01-20 | 2004-06-01 | Agresearch Limited | Dispositivo de administracion a los rumiantes de sustancias utiles. |
| US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
| AUPN353695A0 (en) | 1995-06-14 | 1995-07-06 | Commonwealth Scientific And Industrial Research Organisation | Immunogenic preparation and method for improving the productivity of ruminant animals |
| WO1998007830A2 (en) * | 1996-08-22 | 1998-02-26 | The Institute For Genomic Research | COMPLETE GENOME SEQUENCE OF THE METHANOGENIC ARCHAEON, $i(METHANOCOCCUS JANNASCHII) |
| US5985907A (en) * | 1998-08-12 | 1999-11-16 | Health Research, Inc. | Method for inhibiting growth of methanogens |
| WO2002077183A2 (en) | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| AU2002326949A1 (en) | 2001-09-18 | 2003-05-12 | The Board Of Regents Of The University Of Nebraska | Method for the inhibition of methanogenesis |
| US7314974B2 (en) * | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
| US20060068386A1 (en) * | 2002-03-04 | 2006-03-30 | Alexei Slesarev | Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof |
| SE523209C2 (sv) * | 2002-05-14 | 2004-04-06 | Akzo Nobel Nv | Förfarande för att reducera metanbildningen från matspjälkningsaktiviteter hos djur |
| US20100048595A1 (en) | 2005-03-23 | 2010-02-25 | Washington University In St. Louis | Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota |
| BRPI0817299A8 (pt) * | 2007-09-25 | 2019-01-29 | Pastoral Greenhouse Gas Res Limited | vacinas e componentes de vacina para inibição de células microbianas |
| CN101434924A (zh) * | 2008-12-17 | 2009-05-20 | 中南大学 | 一种分离严格厌氧产甲烷古菌的方法 |
| AR077992A1 (es) * | 2009-08-27 | 2011-10-05 | Pastoral Greenhouse Gas Res Ltd | Secuencia del genoma completo del metanogeno methanobrevibacter ruminantium |
| CN101864362B (zh) * | 2010-05-19 | 2012-05-09 | 江苏加德绿色能源有限公司 | 一种复合微生物菌剂及其应用 |
| DE102011119230B4 (de) * | 2011-11-23 | 2013-07-11 | Audi Ag | Kraftwagen-Blinkleuchte und Verfahren zum Betreiben einer Blinkleuchte |
| JP2016511630A (ja) * | 2012-12-21 | 2016-04-21 | ダニスコ・ユーエス・インク | 代案の下流メバロン酸経路を使用するイソプレン、イソプレノイド、およびイソプレノイド前駆体の生成 |
-
2008
- 2008-09-25 BR BRPI0817299A patent/BRPI0817299A8/pt not_active Application Discontinuation
- 2008-09-25 JP JP2010526839A patent/JP5558356B2/ja not_active Expired - Fee Related
- 2008-09-25 WO PCT/NZ2008/000247 patent/WO2009041830A2/en not_active Ceased
- 2008-09-25 AU AU2008304018A patent/AU2008304018A1/en not_active Abandoned
- 2008-09-25 BR BR122020023381-8A patent/BR122020023381B1/pt active IP Right Grant
- 2008-09-25 US US12/678,936 patent/US8592556B2/en active Active
- 2008-09-25 BR BR122021010729-7A patent/BR122021010729B1/pt active IP Right Grant
- 2008-09-25 WO PCT/NZ2008/000249 patent/WO2009041832A2/en not_active Ceased
- 2008-09-25 DK DK08834203.5T patent/DK2203466T3/en active
- 2008-09-25 CN CN2008801094507A patent/CN102015755A/zh active Pending
- 2008-09-25 AR ARP080104173A patent/AR068553A1/es active IP Right Grant
- 2008-09-25 ES ES08834203.5T patent/ES2587595T3/es active Active
- 2008-09-25 CA CA2700129A patent/CA2700129C/en active Active
- 2008-09-25 JP JP2010526841A patent/JP6067209B2/ja active Active
- 2008-09-25 ES ES08834643.2T patent/ES2625144T3/es active Active
- 2008-09-25 UY UY31361A patent/UY31361A1/es active IP Right Grant
- 2008-09-25 CA CA2700162A patent/CA2700162C/en active Active
- 2008-09-25 US US12/678,976 patent/US9296789B2/en active Active
- 2008-09-25 UY UY31360A patent/UY31360A1/es not_active Application Discontinuation
- 2008-09-25 MX MX2010003328A patent/MX2010003328A/es active IP Right Grant
- 2008-09-25 RU RU2010116163/10A patent/RU2528854C2/ru not_active IP Right Cessation
- 2008-09-25 WO PCT/NZ2008/000248 patent/WO2009041831A1/en not_active Ceased
- 2008-09-25 AR ARP080104171A patent/AR068551A1/es unknown
- 2008-09-25 CL CL2008002859A patent/CL2008002859A1/es unknown
- 2008-09-25 EP EP17206527.8A patent/EP3327030B1/en active Active
- 2008-09-25 EP EP08834203.5A patent/EP2203466B1/en active Active
- 2008-09-25 BR BRPI0817312-5A patent/BRPI0817312B1/pt active IP Right Grant
- 2008-09-25 AR ARP080104172A patent/AR068552A1/es unknown
- 2008-09-25 MX MX2010003319A patent/MX340736B/es active IP Right Grant
- 2008-09-25 DK DK17206527.8T patent/DK3327030T3/da active
- 2008-09-25 CL CL2008002861A patent/CL2008002861A1/es unknown
- 2008-09-25 AU AU2008305846A patent/AU2008305846A1/en not_active Abandoned
- 2008-09-25 DK DK08834643.2T patent/DK2203467T3/en active
- 2008-09-25 AU AU2008304019A patent/AU2008304019A1/en not_active Abandoned
- 2008-09-25 EP EP08833501A patent/EP2203470A4/en not_active Ceased
- 2008-09-25 ES ES17206527T patent/ES2895908T3/es active Active
- 2008-09-25 JP JP2010526840A patent/JP5552053B2/ja not_active Expired - Fee Related
- 2008-09-25 NZ NZ745324A patent/NZ745324A/en unknown
- 2008-09-25 EP EP21181143.5A patent/EP3936516A1/en active Pending
- 2008-09-25 EP EP08834643.2A patent/EP2203467B1/en active Active
- 2008-09-25 CL CL2008002860A patent/CL2008002860A1/es unknown
- 2008-09-25 US US12/678,925 patent/US8586709B2/en active Active
- 2008-09-25 CN CN200880109364.6A patent/CN101918431B/zh active Active
- 2008-09-25 MX MX2010003321A patent/MX2010003321A/es active IP Right Grant
- 2008-09-25 CN CN200880109156.6A patent/CN101932595B/zh active Active
- 2008-09-25 BR BR122021010737-8A patent/BR122021010737B1/pt active IP Right Grant
- 2008-09-25 CN CN201611216760.1A patent/CN107129524B/zh active Active
- 2008-09-25 CA CA2700164A patent/CA2700164C/en active Active
- 2008-09-25 UY UY31359A patent/UY31359A1/es not_active Application Discontinuation
-
2010
- 2010-03-18 ZA ZA2010/01933A patent/ZA201001933B/en unknown
-
2013
- 2013-10-25 US US14/063,640 patent/US20140220636A1/en not_active Abandoned
-
2014
- 2014-07-04 JP JP2014139171A patent/JP2015042166A/ja active Pending
- 2014-08-08 AU AU2014210649A patent/AU2014210649B2/en active Active
-
2016
- 2016-03-28 US US15/082,373 patent/US10590170B2/en active Active
- 2016-10-05 JP JP2016197575A patent/JP2017046704A/ja active Pending
-
2020
- 2020-02-10 US US16/786,665 patent/US10995120B2/en active Active
-
2021
- 2021-04-08 US US17/226,028 patent/US11926647B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008002860A1 (es) | Polipeptido; polinucleotido que lo codifica; vector y fago aislado que comprenda este polinucleotido; anticuerpo que se une a este polipeptido; molecula de fusion que comprende este polipeptido; celula huesped metanogena que comprende el vector; composicion farmaceutica que comprende el polinucleotido. | |
| CY1125349T1 (el) | Αγωνιστικοι παραγοντες δεσμευσης του υπολοχεα tnf | |
| CL2009000459A1 (es) | Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso. | |
| CL2013002040A1 (es) | Anticuerpo biespecifico o fragmento del mismo que se une especificamente a il-13 e il-14; molecula de acido nucleico que lo codifica; vector; celula; composicion farmaceutica; y sus usos (div.sol.n°3037-08). | |
| CL2013002623A1 (es) | Moleculas de union biespecificas que comprende al menos un componente que se une a vegf y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula. | |
| CL2015001709A1 (es) | Etiqueta de péptido que se une a hialuronano; ácido nucleico que la codifica; vector; célula hospedera; molécula etiquetada con dicho péptido; composición que la comprende; y método de producción de etiqueta de péptido. | |
| CL2008002444A1 (es) | Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente. | |
| CL2010001457A1 (es) | Molecula de acido nucleico que codifica delta endotoxinas de bacillus thuringiensis; constituciones moleculares quer comprenden dichos polinucleotifdos, anticuerpos que se asocian especificamente a las endotoxinas, y procedimiento para el control de plagas de insectos. | |
| CL2013000596A1 (es) | Moleculas de union a vegf; molecula de acido nucleico que la codifica; celula hospedante; composicion farmaceutica; uso de la composicion para tratar efectos sobre la angiogenesis mediados por el vegf. | |
| CY1112924T1 (el) | Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης | |
| CL2009000379A1 (es) | Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer. | |
| CL2014002072A1 (es) | Polipéptidos de unión a cx3cr1; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo contiene; metodo de elaboracion del peptido; usos del peptido; kit que contiene el peptido. | |
| MX374682B (es) | Moléculas de unión a 4-1bb. | |
| CL2015001353A1 (es) | Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer. | |
| BR112012009854B8 (pt) | proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma | |
| CL2008001674A1 (es) | Dominio variable simple (dab) de inmunoglobulina anti-fator de crecimiento endotlial vascular (vegf); acido nucleoico que lo codifica; vector y celula huesped; metodo de produccion; antagonosta de vegf que comprende el dab; composiicon que comprende al antagonista; y uso del antagonista para prepara un medicamento. | |
| BR112016008125A2 (pt) | moléculas de ligação de domínio de fibronectina tipo iii modificadas com cisteína | |
| CL2013000669A1 (es) | Agente de union a cd33 que se une al cd33 humano; molecula de adn que codifica la region variable de cadena pesada de un agente de union a cd33; vector de expresion; celula hospedante; metodo para reducir agente de unión a cd33; composicion farmaceutica; uso de la composicion farmaceutica para disminuir el numero de celulas que expresan el cd33 sobre su superficie. | |
| CL2014000631A1 (es) | Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
| AR070314A1 (es) | Uso de peptidos de transito a plastidos derivados de glaucocystophytas | |
| EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
| EA201270758A1 (ru) | Мутанты fgf21 и их применение | |
| MX385926B (es) | Proteínas de fusión de citoquinas. | |
| CL2009000862A1 (es) | Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer. | |
| WO2009034190A3 (en) | Affinity tag |